Cancer

Published today in Clinical Cancer Research, findings from a study led by investigators at the Vall d’Hebron Institute of Oncology (VHIO), which forms part of the Vall d’Hebron Campus, underscore the efficacy of analyzing circulating […]

Lymphedema after head and neck cancer is considerably more common than previously assumed and can persist long after cancer treatment has finished. Researchers at Lund University in Sweden have discovered that patients with a low […]

People aged 80 and older with a common type of lymphoma can take a half-dose of chemotherapy and be cured or significantly extend their survivorship with fewer toxic side effects, a new study shows.This article […]

EPFL researchers have successfully engineered cells of the immune system to more effectively recognize cancer cells. The work, covered in two papers, turns the previously lab-based method into a full-blown immunotherapy strategy.This article was originally […]

Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States. Over 80% of lung cancers are non-small cell lung cancers, in which tumor cells are larger and […]

A research group at the Italian Institute of Technology (IIT-Istituto Italiano di Tecnologia) has identified a candidate molecule that could improve current therapies against pancreatic cancer. The team designed the new molecule, called Apt1, using […]

Chemotherapy drugs that target cancer cells without damaging normal cells remain one of the key goals of precision medicine in cancer treatment. The challenge is designing drugs that do this effectively.This article was originally published […]

Compared with white patients, Black patients with an aggressive form of leukemia—called acute myeloid leukemia (AML)—were on average more than five years younger at diagnosis and more than 30% more likely to die of their […]

Cedars-Sinai investigators, leading a multi-institutional team, have developed and validated a tool to predict which patients with pancreatic neuroendocrine tumors (PanNETs) need closer monitoring because their cancer is more likely to recur.This article was originally […]

University of California, San Francisco investigators led WISDOM, a randomized comparison of risk-based breast cancer screening and annual mammography. Rates of stage ≥IIB breast cancers met a noninferiority threshold under risk-based screening, and breast biopsy […]